MD Anderson

After Diagnosis, Another Hurdle: Cancer Screening for the Cancer Patient

by Jude Richard

Scared, mystified, sometimes both—that's how Therese Bevers, M.D., medical director of the Cancer Prevention Center (CPC) at The University of Texas M. D. Anderson Cancer Center, says many cancer patients feel when they first come for cancer screening. “The occasional patient is so shocked already by the diagnosis of his or her first primary cancer,” says nurse practitioner Mervianna Thompson, R.N., C.S., A.N.P., A.O.C.N., who screens patients in the CPC daily, “that they can’t handle screening and the possibility that another cancer will be found.” But when they leave—after they understand screening’s benefits—they’re often thinking differently. “The cancer patient must be reminded,” advises Lewis Foxhall, M.D., “that having one cancer may make it more likely he’ll have a

(Continued on next page)
second primary and that, consequently, the patient needs to stay healthy and have recommended regular screening." Dr. Foxhall, who formerly referred patients to M. D. Anderson from a primary care practice, now is co-medical director of M. D. Anderson's Office of Referral Relations.

Educating the patient is part of the process, Thompson agrees. "We first explain we're looking for other cancers before they become more advanced, which requires more extensive treatment."

The patients' own experience with early detection of a primary cancer can make the search for second primaries palatable, according to Dr. Bevers. "Often, when we establish that a patient has a good chance of survival because the cancer was caught early, we use that example to convince the patient of the need for continued screening," she said.

Furthermore, patients aren't the only ones unsure about screening in cancer patients. Members of the American Society of Clinical Oncology said in a survey reported in 1992 that lack of patients in their practice without cancer and the difficulty of incorporating screening economically into practice were major barriers to putting cancer screening and prevention activities into practice.

For the best patient outcome, primary physician, oncologist, and patient must cooperate in screening efforts. If not performed by the oncologist during workup, screening may be done by the community physician if indicated based on the projected outcome of the cancer treatment.

"Communication between the oncologist and the community physician is key since the community physician often keeps seeing the patient while the patient is being treated over time for the cancer," says Dr. Foxhall.

Treatment, too, is shifting after diagnosis at major centers like M. D. Anderson to treatment near home. "Occasionally, recommended treatment is being done in the community, after centers like ours have done the initial screening and workup," said Thompson. "The community physician is then more involved in screening the patient on a regular basis and sends the patient back to the oncologist for regular checkups."

When the community physician will be performing the screening, Dr. Bevers said the oncologist must make clear to the community physician the outlook for the patient, including "the exact ramifications of the patient's tumor stage and grade, treatment, treatment-related side effects, and expected five-year survival and recurrence rates."

"Certain cancers have certain life expectancies, and at some point, screening for other life-threatening conditions may no longer be of benefit to the patient," she said. "But until that point, the patient should continue being screened."

Once determined necessary, however, screening should be regular.

"Wherever the screening is done and whoever does it, vigilance must increase," according to Dr. Foxhall.

"What cancer patient, oncologist, and community physician must all remember is that the patient is more susceptible to other cancers and other illnesses and that concerted primary surveillance and secondary screening is necessary," said Thompson.

Dr. Foxhall said that in his experience, patients often became more willing to be regularly screened after they have had a cancer diagnosed: "The diagnosis of that first primary cancer breaks down the barrier of patient denial and gives the oncologist and community physician a persuasive toehold."

"The community physician ... can be crucial in reducing cancer mortality."

— Lewis Foxhall, M.D., co-medical director, M. D. Anderson's Office of Referral Relations

"More and more patients are also asking for genetic screening," Dr. Bevers says, despite its high cost and their awareness that the results, even though confidential, can raise new fears and concerns when a genetic marker linked to cancer is found.

"But because it's highly specialized and involves DNA sequencing," Dr. Bevers adds, "most national medical associations recommend that the community physician defer to comprehensive cancer centers for such screening. However, both the patient and the community physician can stay alert to any signs of genetic predisposition to disease." Such a predisposition would include a strong family history of cancer, such as breast, ovarian, colon, or endometrial cancer.
At present, genetic screening can be done for colon, breast, ovarian, and thyroid cancers. M. D. Anderson offers these tests.

But Dr. Bevers points out that community physicians can do a great deal of screening in the office. What they may not be able to do (e.g., sigmoidoscopy), they can order. Results can then be forwarded to the oncologist.

"The community physician," says Dr. Foxhall, "by providing preventive clinical services to try to detect cancer during its asymptomatic phase when treatment can be most effective, can be crucial in reducing cancer mortality."

For the busy community physician who wants to improve his or her screening program, whether for those with a history of cancer or without it, Dr. Foxhall recommends a program developed by the U.S. Public Health Service and now being promoted by major medical associations called "Put Prevention Into Practice," or PPIP.

Through the Agency for Health Care Policy and Research web site (http://www.ahcpr.gov/ppip), community physicians and other primary care providers have access to useful patient health questionnaires, flow charts, patient education materials, reminder postcards, and record-keeping tools meant to organize and streamline screening in a busy practice. PPIP materials are also available through the Texas Department of Public Health.

Thompson points out that patients, too, can lead the early detection effort. "Patients can keep educating themselves and keep reminding their own personal physicians of the need for routine screening," she said. ●

**For more information,** contact the Cancer Prevention Center at (713) 745-8040 or Dr. Foxhall at (713) 792-2202.

E-mail Dr. Bevers at bevers@notes.mdacc.tmc.edu and Dr. Foxhall at ifoxhall@mdanderson.org.

---

**M. D. Anderson Researchers Study Children’s School Lunch Habits and Choices**

Low scores by the nation’s schoolchildren are sending researchers scurrying. But this time it is to the lunchroom, not the classroom.

Research shows that children consume fewer than 2.5 servings of fruits and vegetables daily, giving them a score below 50% on the test of eating five servings per day. This dismal score so early in life worries cancer prevention experts who say that meeting the standard may reduce the risk of cancer by 30% to 40%.

To get answers, researchers are conducting a pilot study to determine what food choices children make when selecting from an array of sweets, high-fat snacks, fruits, and vegetables as lunch choices.

"If children are given freedom of choice in selecting food for lunch, will their diets change for the worse?" asks Karen Cullen, DrPH, principal investigator for the two-year study funded by the Cancer Research Foundation of America. Dr. Cullen is an assistant professor in the Department of Behavioral Science at the University of Texas M. D. Anderson Cancer Center.

As part of the study, 600 students at one middle school and four elementary schools in Texas City are filling out daily food diaries for a week, recording for the researchers what they choose to eat for lunch.

Recent studies show that the National School Lunch Program meals provide a significant amount of fruit and vegetables for third-grade children, says Dr. Cullen. But no research to date has examined what happens to children’s diets when they move into middle and junior high schools, where snack bars offer competing foods, such as candy, chips, and soft drinks.

"We know that poor nutrition is a risk factor for colorectal, prostate, and possibly breast cancers," says Dr. Bernard Levin, M. D. Anderson’s vice president for cancer prevention. "We ultimately want to reduce the number of cancers by seeing people begin in childhood to practice healthy nutrition habits that last a lifetime," he said.

Investigators also will examine whether children change their eating habits over the course of the school year, perhaps choosing nutritious foods after the novelty of having less healthy foods available has worn off.

"This research will provide important information to enable us to develop and implement middle school nutrition behavior change programs to influence children’s choices of fruit, vegetables, and low-fat foods," says Dr. Ellen Gritz, chair of the Department of Behavioral Science.

Results of this study may also enable schools to offer more healthful lunch choices in a manner more acceptable to students, says Dr. Cullen. ●

**For more information,** contact Dr. Cullen at (713) 745-2847.
The University of Texas M. D. Anderson Cancer Center is recruiting women for a multinational study meant to further define tamoxifen's role in reducing breast cancer risk by comparing it with raloxifene. The study aims to determine which is more effective in reducing breast cancer risk and which has fewer side effects in postmenopausal women at high risk for breast cancer.

Tamoxifen, used as the control in this National Cancer Institute-supported trial, was found last year in a double-blind study of 13,000 pre- and postmenopausal women to halve the women's risk of breast cancer compared with that of controls. Researchers cut the trial short when tamoxifen's effectiveness became apparent.

The new trial, one of the largest breast cancer prevention studies ever, expects to enroll 22,000 women at more than 400 centers across the United States, Canada, and Puerto Rico. Called the STAR trial (Study of Tamoxifen And Raloxifene), the research is part of the National Surgical Adjuvant Breast and Bowel Project. M. D. Anderson plans to enroll 400 participants. Other study sites in Texas include ones in Lufkin and El Paso.

"We are excited about bringing the STAR trial to the greater Houston metropolitan area," said Dr. Therese Bevers, principal investigator at M. D. Anderson. "Women everywhere are at risk for breast cancer, and we are pleased that Houston-area women will have the chance to participate in this important study."

Side effects are a major safety interest because women who took tamoxifen in the earlier study benefited from having fewer fractures of the hip, wrist, and spine than did controls, but they also experienced increased risk of endometrial cancer, deep vein thrombosis, pulmonary embolism, and possibly stroke.

"Tamoxifen is a medically proven intervention but is not perfect," said Dr. Bevers. "Women who are at increased risk of breast cancer need options for preventing this disease with a minimum of side effects, and STAR is a concerted effort to find one."

Information about the safety of raloxifene is limited, according to Dr. Bevers. Raloxifene was approved in December 1997 by the U.S. Food and Drug Administration (FDA) to prevent osteoporosis and has been in breast cancer clinical trials for about five years. In a three-year study conducted by the University of California, San Francisco (UCSF), raloxifene decreased the risk of breast cancer in postmenopausal women with osteoporosis by 76%.

"Women taking raloxifene in studies of osteoporosis have had an increased chance of deep vein thrombosis or pulmonary embolism similar to the risk seen with tamoxifen. But neither in these studies nor in the UCSF study did raloxifene increase the risk of endometrial cancer.

Women who participate in STAR must be postmenopausal, at least age 35, and have an increased risk of breast cancer as determined by their age, family history of breast cancer, personal medical history, age at first menstrual period, and age at birth of their first child.

Once a woman chooses to participate, she will be randomly assigned to receive either 20 mg of tamoxifen or 60 mg of raloxifene daily for five years and will have regular follow-up examinations, including mammograms and gynecologic exams.

Tamoxifen's manufacturer, Zeneca Pharmaceuticals of Wilmington, Delaware, and the maker of raloxifene, Eli Lilly and Company of Indianapolis, Indiana, are providing drugs for the trial without charge.

For more information about STAR, visit M. D. Anderson's web site at http://www.mdanderson.org, the National Surgical Adjuvant Breast and Bowel Project web site at http://www.nsabp.pitt.edu, or the National Cancer Institute's clinical trials web site at http://cancertrials.nci.nih.gov. Additional information is also available by phone from M. D. Anderson's STAR line at (713) 792-8064 or from the Cancer Information Service at (800) 4-CANCER.
You've heard it many times: early detection of cancer saves lives. By catching the disease at an early stage, treatment is more likely to be successful. But while most of us are aware of the value of regular cancer screening examinations, many of us are confused about how often we should get these checkups.

Cancer-related Checkup
In addition to age- and sex-specific cancer screening examinations done for cancers of the breast, cervix, endometrium, prostate, colon, and rectum, the American Cancer Society recommends that adults between the ages of 20 and 40 years have a cancer-related checkup every three years. Once the person reaches 40, the recommendation is for a yearly checkup. Such an examination should include health counseling and, depending on the person's age and sex, might include examinations for cancers of the thyroid, skin, oral cavity, lymph nodes, testes, and ovaries.

Tests for Women
M. D. Anderson Cancer Center encourages women between the ages of 20 and 39 years to perform breast self-examinations each month and to undergo a breast examination by a health professional every one to three years. For women 40 years and older, experts add an annual mammogram and make the professional breast examination an annual requirement. The examination performed in the clinic should occur near the time of the mammogram. Throughout life, women are encouraged to perform breast self-examinations monthly.

M. D. Anderson also recommends that all women have an annual pap smear to check for cervical cancer. Women who are at high risk for cancer of the uterus should, according to the American Cancer Society, have a sample of their endometrial tissue examined when menopause starts.

Tests for Men
Men age 50 to 70 years should have a prostate-specific antigen blood test and a digital rectal examination by a health professional annually, according to M. D. Anderson Cancer Center recommendations. To detect testicular cancer early, men should perform a monthly testicular self-examination to check for lumps or other changes in their testicles.

Colon and Rectum Examinations
M. D. Anderson recommends that men and women who are 50 years or older should have one of the following combinations of examinations:
- A yearly fecal occult blood test (a sample of stool is examined for blood) and a flexible sigmoidoscopy (an examination of the rectum and lower colon with a slender, lighted instrument) every five years; or
- A colonoscopy (an examination of the rectum and entire colon with a lighted instrument) every 10 years; or
- A double-contrast barium enema every 5 to 10 years.

A digital rectal examination should be performed at the same time as the sigmoidoscopy, colonoscopy, or double-contrast barium enema. People who are at higher-than-average risk for colorectal cancer should consult their doctor about a recommended testing schedule.

Skin and Oral Cavity Examinations
Skin cancer is the most common cancer, but most cases are highly curable. Melanoma, skin cancer's most serious form, is occurring more frequently; its incidence rate has more than doubled in the last two decades. Experts recommend that adults practice self-examination regularly, and some say yearly examinations by a physician are necessary if risk is higher than average.

Dentists and physicians should check the oral cavity at regular checkups for changes in the lining of the oral cavity.

These various screening examinations can detect cancers of the breast, cervix, colon, rectum, prostate, testes, oral cavity, and skin at the earliest and most treatable stages. These cancers, according to the American Cancer Society, account for about half of all new cancer cases. The five-year relative survival rate for patients with these cancers is about 81%.

(713) 792-6161 outside the United States.
June 1999
© 1999 The University of Texas
M. D. Anderson Cancer Center
Nerve Grafting Attempts to Restore Erectile Function After Prostatectomy

by Dawn Chalaire

Despite advances in surgical techniques and postoperative therapies, the fact remains that for many men with localized prostate cancer the price of a potentially curative radical prostatectomy is permanent sexual dysfunction.

"Sexual functioning is an important part of a man's life," said Christopher G. Wood, M.D., assistant professor of urology and cancer biology at The University of Texas M. D. Anderson Cancer Center. "To suggest to men that they need to give that up in the name of cancer control forces them to make a very difficult and heartbreaking decision. With the sural nerve graft, we’re offering an opportunity to maximize cancer control and improve their quality of life."

Dr. Wood is the principal investigator in a phase I study to test the safety and efficacy of using autologous sural nerve grafts to preserve erectile function following radical retropubic prostatectomy. Although this particular study is being conducted exclusively at M. D. Anderson, Baylor College of Medicine Assistant Professor of Urology Edward D. Kim is one of the study’s coinvestigators. Dr. Kim, who has a special interest in erectile dysfunction and infertility, and colleagues at Baylor are also performing the procedure.

While there may be other causes of erectile dysfunction following radical prostatectomy, removal of the cavernous nerves, located on either side of the prostate gland, is the most common cause of postoperative impotence. The rate of impotence following the removal of both cavernous nerves is essentially 100%.

Depending on the stage, grade, and location of the tumor, one or both of the cavernous nerves are sometimes left intact during prostatectomy. Between 40% and 60% of patients who undergo unilateral nerve-sparing surgery retain the ability to have spontaneous erections. Some evidence suggests, though, that leaving the cavernous nerves intact increases a patient’s risk of both positive tumor margins and recurrence. The nerve bundles are a common site of prostate cancer and may even provide a pathway for the cancer to spread outside the prostate, according to Dr. Wood.

"By removing both nerves, you definitely are going to improve cancer control at the expense of impotence after surgery," Dr. Wood said. "So the advantage of sural nerve grafting is to potentially address that problem of impotence while still optimizing cancer control."

To be eligible, patients must be candidates for radical prostatectomy but have clinically localized disease that requires bilateral removal of the cavernous nerves. They must also have normal erectile function before surgery. Dr. Kim conducts pre- and postoperative evaluations. Preoperative evaluation includes a physical examination, completion of a questionnaire about the patient's sexual history, and a determination of baseline erectile functioning. The fairly common patient complaint that penile length decreases following radical prostatectomy prompted investigators to add evaluation of pre- and postoperative erectile length to the study’s measures.

Other study coinvestigators at M. D. Anderson include Richard

---

"The initial results are quite encouraging."

— Christopher G. Wood, M.D.
Babaian, M.D., professor of urology, and Drs. Stephen Kroll and David Chang, professors of plastic surgery. One plastic surgeon and one urologist typically work together during the three- to four-hour combined prostatectomy and nerve-grafting procedure.

The plastic surgeon harvests a section of the sural nerve through an incision in the back of the lower right leg. Following the removal of the prostate and surrounding nerve bundles by the urologist, the plastic surgeon cuts the sural nerve in half and grafts it onto the preserved stumps of each cavernous nerve. Surgeons use loupes for magnification during suturing and must take care to avoid tension on the nerve grafts. The only permanent side effect of the sural nerve harvest is numbness in an area about the size of a half dollar on the outside of the ankle.

Four to six weeks after surgery, Dr. Kim initiates erectile dysfunction therapy. Research indicates that beginning therapy as soon as possible after surgery improves a patient's chances of being able to have spontaneous erections. Therapy options include sildenafil (Viagra) taken orally; penile injections of papaverine, prostaglandin E1, and phenolamine (Trimix); a vacuum erection device; and use of the medicated urethral system for erection (MUSE). MUSE includes the insertion of a pellet of prostaglandin into the urethra through the tip of the penis. Patients return at 3, 6, 12, and 24 months after surgery for assessment of erectile function.

So far, 10 patients have undergone prostatectomy with bilateral nerve grafting at M. D. Anderson, where the enrollment target is 30 patients. None of those patients have completed the 14 months of follow-up investigators think is necessary to determine if the procedure has been successful, but some patients have reported by telephone that they are having erections. At Baylor, Dr. Kim's initial results indicate a success rate of about 60% among the 15 patients who have undergone the surgery and passed the 14-month postoperative evaluation point.

"One of the things that should be emphasized is that this is a research study. While the initial results are quite good, I do believe that it's going to be very much surgeon dependent, on the part of both the plastic surgeon and the urologist involved in the case," Dr. Wood said.

The concept of using autologous nerve grafting to maintain erectile function is not new. In a 1991 laboratory study, the genitofemoral nerve was used to replace the cavernous nerves following radical retropubic prostatectomy in rats, resulting in a significant return of erectile function. But a subsequent attempt to use genitofemoral nerve grafting in humans was not successful, the procedure became controversial, and many urologists abandoned the idea.

"This is not something that everyone has signed on to," Dr. Wood said. "Actually, most people have not, but our approach to it has been: it's an unknown, the initial results are quite encouraging, and it's something we should evaluate."

One of the arguments against the grafting centers around the differences in impulse conduction believed to occur when the sural nerve, which is myelinated, is used to replace the unmyelinated cavernous nerve. Dr. Wood points out that grafted nerves eventually become unmyelinated and serve as a scaffold, rather than a bridge, for nerve fibers at one end to grow back to the other side.

According to Dr. Kroll, it is not that nerve grafting is inappropriate, it is that grafting is complex. He said the difficulty involved with attempting a nerve-grafting procedure so deep within the pelvic cavity might explain why the technique has not been successful before, even though the concept behind it is sound.

"Nerve grafting is a well-accepted procedure that has been done for many years with a high rate of success," he said. "It's not a new idea to repair nerves." He said the procedure is "just a logical extension of traditional plastic surgery to a new area."

For more information, contact Dr. Kroll at (713) 794-1247 or Dr. Wood at (713) 792-3250.
**Staff Publications in June**

Below is a partial list of staff publications appearing this month.


- **Molldrem JI et al.** A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. *Cancer Res* 1999;59(11):2675-81.


- **Shin HJ, Sneige N, Staeckel GA.** Utility of punch biopsy for lesions that are hard to aspirate by conventional fine-needle aspiration. *Cancer* 1999;87(3):149-54.


---

**OncoLog**

The University of Texas
M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas 77030

President
John Mendelsohn, M.D.

Senior Vice President and Chief Academic Officer
Margaret L. Kripke, Ph.D.

Academic Programs
Robin R. Sandler, M.D.

Director, Department of Scientific Publications
Walter J. Pagel

Managing Editor
Beth W. Allen

Contributing Editors
Dawn Chalaire
Stephanie Deming
Maureen Goode, Ph.D.
Kimberly JT Herrick
Suni Hosemann
Don Norwood
Beth Norton
Jude Richard
Alison Ruffin
Julia M. Starr
Vickie J. Williams
Michael S. Worley

Design
Matara Design
Photography
Jim Lemoine

Editorial Board
W. K. Alfred Yung, M.D., Chair
Robert Benjamin, M.D.
Therese Bevers, M.D.
Thomas Burke, M.D.
David Galland, M.D.
Steven Garley, M.D.
Frank Fossella, M.D.
Lewis Foxhall, M.D.
James Gajewski, M.D.
Martyn Hoagill
Jeffrey Lee, M.D.
Moche Mao, M.D.
Geoffrey Robb, M.D.
Rena Sellin, M.D.
David Swanson, M.D.
Richard Theriault, D.O.
David Tubergen, M.D.

Published by the Department of Scientific Publications—234, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.

Made possible in part by a gift from the late Mrs. Harry C. Weiss. Not printed at state expense. ©1999 The University of Texas M. D. Anderson Cancer Center.

Printed on recycled paper

MD Anderson OncoLog

Department of Scientific Publications—234
M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas 77030

www.mdacc.tmc.edu/~oncolog

Address Service Requested